INIS Swings to Loss Amidst Revenue Dip, Eyes $12.5M Asset Sale

TL;DR

**INIS is bleeding cash and needs that $12.5M asset sale to close, or this stock is dead money.**

AI Summary

INTERNATIONAL ISOTOPES INC. (INIS) reported a net loss of $203,601 for the three months ended September 30, 2025, a significant decline from a net income of $150,251 in the same period of 2024. For the nine months ended September 30, 2025, the net loss widened to $477,080, compared to a net loss of $237,245 in the prior year. Revenue from product sales decreased to $3,277,816 for the three-month period in 2025 from $3,924,444 in 2024, but slightly increased for the nine-month period to $10,172,036 from $9,998,135. Operating costs and expenses for the nine months ended September 30, 2025, were $6,494,886, a decrease from $6,599,765 in the prior year. The company is focusing on its Theranostics, Cobalt, and Calibration & Reference Products segments, and is developing its Medical Device segment, including an EasyFill Automated Iodine Capsule System. A key strategic development is the pending sale of its Fluorine Products segment and the Planned Uranium De-Conversion Facility for $12.5 million, with a closing deadline of March 31, 2026, subject to NRC approval and buyer financing. Cash provided by operating activities decreased significantly to $210,043 for the nine months ended September 30, 2025, from $568,215 in the same period of 2024.

Why It Matters

INIS's widening net losses and declining cash from operations signal potential financial strain, making the $12.5 million asset sale of its Fluorine Products segment critical for its future liquidity. Investors should note the uncertainty surrounding this sale, as it hinges on NRC approval and buyer financing by March 31, 2026. For employees, the strategic shift towards core segments and medical devices, alongside the potential divestiture, could impact job roles and company direction. Customers might see continued focus on Theranostics, Cobalt, and Calibration & Reference products, but the delay in the De-Conversion Facility sale could affect long-term supply chain stability in the broader radioisotope market, especially given the unique NRC license held by INIS.

Risk Assessment

Risk Level: high — The company reported a net loss of $477,080 for the nine months ended September 30, 2025, and a significant decrease in net cash provided by operating activities to $210,043 from $568,215 in the prior year. The pending $12.5 million sale of the Fluorine Products segment is crucial for liquidity, but it is contingent on buyer financing and NRC approval by March 31, 2026, introducing substantial uncertainty.

Analyst Insight

Investors should exercise extreme caution and consider divesting, or at minimum, hold off on new positions until the $12.5 million asset sale is finalized and the company demonstrates a clear path to profitability. Monitor the NRC approval process and buyer financing for the Fluorine Products segment sale closely, as its failure could severely impact INIS's ability to fund operations.

Financial Highlights

debt To Equity

3.36

revenue

$10,172,036

operating Margin

-63.84%

total Assets

$17,846,637

total Debt

$13,750,802

net Income

-$477,080

eps

N/A

gross Margin

60.08%

cash Position

$1,651,548

revenue Growth

+1.74%

Revenue Breakdown

Key Numbers

• $203,601 — Net loss for Q3 2025 (Compared to $150,251 net income in Q3 2024, indicating a significant swing to loss.)
• $477,080 — Net loss for nine months ended Sept 30, 2025 (Widened from $237,245 net loss in the same period of 2024.)
• $3,277,816 — Product sales for Q3 2025 (Decreased from $3,924,444 in Q3 2024.)
• $10,172,036 — Product sales for nine months ended Sept 30, 2025 (Slightly increased from $9,998,135 in the same period of 2024.)
• $210,043 — Net cash provided by operating activities for nine months ended Sept 30, 2025 (Significantly decreased from $568,215 in the same period of 2024.)
• $12.5 million — Proceeds from planned asset sale (Expected from the sale of Fluorine Products segment and De-Conversion Facility, critical for future liquidity.)
• March 31, 2026 — Outside Date for asset sale closing (Deadline for the Fluorine Products segment and De-Conversion Facility sale, subject to conditions.)
• 528,209,538 — Common shares outstanding (As of November 12, 2025.)

Key Players & Entities

• INTERNATIONAL ISOTOPES INC. (company) — registrant
• Radnostix, LLC (company) — wholly-owned subsidiary
• RadQual, LLC (company) — wholly-owned subsidiary
• TI Services, LLC (company) — wholly-owned subsidiary
• AMICI, Inc. (company) — seller of medical devices and assets
• Alpha Nuclide Inc (company) — joint venture partner for China distribution
• Nuclear Regulatory Commission (regulator) — approves license transfers
• Lea County, New Mexico (location) — site of planned uranium de-conversion facility
• Bloomberg (company) — publisher

FAQ

Risk Factors

• Deteriorating Profitability and Cash Flow [high — financial]: The company reported a net loss of $203,601 for Q3 2025, a significant swing from a $150,251 net income in Q3 2024. For the nine-month period, the net loss widened to $477,080 from $237,245. Net cash provided by operating activities decreased substantially to $210,043 from $568,215 year-over-year, indicating increasing financial pressure.
• Dependence on NRC Approval for Asset Sale [high — regulatory]: The planned sale of the Fluorine Products segment and the Planned Uranium De-Conversion Facility for $12.5 million is contingent upon Nuclear Regulatory Commission (NRC) approval. Delays or denial of this approval could jeopardize the transaction and the expected capital infusion.
• Reliance on Asset Sale for Liquidity [high — financial]: The company is relying on the $12.5 million sale of its Fluorine Products segment and De-Conversion Facility, expected to close by March 31, 2026, to bolster its financial position. Failure to complete this sale could significantly impact liquidity, especially given the declining operating cash flow.
• Declining Product Sales in Key Periods [medium — operational]: Product sales for the three months ended September 30, 2025, decreased to $3,277,816 from $3,924,444 in the same period of 2024. While nine-month sales saw a slight increase, the quarterly decline suggests potential headwinds in core product revenue generation.
• Development of New Segments [medium — operational]: The company is investing in developing its Medical Device segment, including the EasyFill Automated Iodine Capsule System. While strategic for future growth, these investments may require significant capital and may not yield immediate returns, potentially impacting short-term profitability.
• Increased Operating Expenses [medium — financial]: Salaries and contract labor increased by 13.2% to $3,368,592 for the nine months ended September 30, 2025, compared to $2,976,880 in the prior year. This increase contributed to the widening net loss despite a slight rise in overall revenue for the period.

Industry Context

The isotope and radiopharmaceutical industry is characterized by high regulatory barriers, specialized manufacturing processes, and a critical role in medical diagnostics and treatments. Companies like INIS operate in a niche market where demand is driven by healthcare needs and scientific research. Competition can be intense, with established players and emerging technologies vying for market share. Trends include the increasing use of targeted therapies and diagnostic imaging, driving demand for specific isotopes.

Regulatory Implications

The company's operations, particularly its involvement with radioactive materials and potential sale of facilities like the Uranium De-Conversion Facility, are subject to stringent oversight by regulatory bodies such as the Nuclear Regulatory Commission (NRC). Compliance with safety, security, and environmental regulations is paramount and can involve significant costs and operational constraints. Changes in regulatory requirements could impact operations and the feasibility of strategic transactions.

What Investors Should Do

1. Monitor the progress and conditions of the Fluorine Products segment and De-Conversion Facility sale.
2. Analyze the drivers behind the widening net loss and declining operating cash flow.
3. Evaluate the strategic rationale and execution risk of the Medical Device segment development.
4. Assess the company's ability to manage its liabilities, particularly the mandatorily redeemable preferred stock and asset retirement obligations.

Key Dates

• 2025-09-30: End of third quarter and nine-month period — Reporting period for the financial results showing a net loss and decreased operating cash flow.
• 2026-03-31: Outside date for asset sale closing — Deadline for the sale of the Fluorine Products segment and De-Conversion Facility, crucial for future liquidity.

Glossary

Mandatorily redeemable convertible preferred stock

A class of preferred stock that has a contractual obligation for the issuer to redeem it at a specified future date or upon the occurrence of a specific event, and which can also be converted into common stock. (Represents a significant long-term liability of $4,063,000, impacting the company's capital structure and financial obligations.)

Asset retirement obligation

A legal obligation associated with the retirement of tangible long-lived assets, such as nuclear facilities, that is incurred upon acquisition, construction, or normal use of the asset. (The company has an obligation of $1,599,724 related to asset retirement, which is a long-term liability that requires future funding.)

Operating lease right-of-use asset

An asset recognized under accounting standards for leases, representing the lessee's right to use an underlying asset for the lease term. (The company has significant operating lease assets ($2,740,704 current and $2,588,123 long-term) and corresponding liabilities, indicating substantial commitments for leased facilities or equipment.)

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its net identifiable assets. (The company has $1,384,255 in goodwill, which is subject to impairment testing and could be written down if the acquired business's value declines.)

Year-Over-Year Comparison

INTERNATIONAL ISOTOPES INC. (INIS) has experienced a significant deterioration in profitability compared to the prior year. For the nine months ended September 30, 2025, the company reported a net loss of $477,080, a substantial increase from a net loss of $237,245 in the same period of 2024. While total revenue saw a slight increase of 1.74% to $10,172,036, gross profit declined due to higher cost of product. Operating expenses, particularly salaries and contract labor, increased, contributing to the wider net loss. Furthermore, net cash provided by operating activities plummeted by 63.05% to $210,043, signaling a weakening cash generation capability.

Key Financial Figures

• $0.01 — , the number of shares of common stock, $0.01 par value, outstanding was 528,209,538

Filing Documents

• inis20250930_10q.htm (10-Q) — 999KB
• ex_857498.htm (EX-31.1) — 9KB
• ex_857499.htm (EX-31.2) — 8KB
• ex_857500.htm (EX-32.1) — 5KB
• ex_857501.htm (EX-32.2) — 5KB
• 0001437749-25-035011.txt ( ) — 5158KB
• inis-20250930.xsd (EX-101.SCH) — 36KB
• inis-20250930_cal.xml (EX-101.CAL) — 43KB
• inis-20250930_def.xml (EX-101.DEF) — 314KB
• inis-20250930_lab.xml (EX-101.LAB) — 293KB
• inis-20250930_pre.xml (EX-101.PRE) — 336KB
• inis20250930_10q_htm.xml (XML) — 771KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements Unaudited Condensed Consolidated Balance Sheets at September 30, 2025 and December 31, 2024 3 Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 4 Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 5 Unaudited Condensed Consolidated Statement of Stockholder's (Deficit) Equity for the Three and Nine Months Ended September 30, 2025 and 2024 6 Notes to Unaudited Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 8 Item 4.

Controls and Procedures

Controls and Procedures 29

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 29 Item 1A.

Risk Factors

Risk Factors 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 31 Item 5. Other Information 31 Item 6. Exhibits 32

Signatures

Signatures 33 2 Table of Contents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (unaudited) September 30, December 31, 2025 2024 Assets Current assets Cash and cash equivalents $ 1,651,548 $ 1,945,523 Accounts receivable 1,970,807 1,521,380 Inventories 1,049,671 820,893 Prepaids and other current assets 305,830 698,030 Total current assets 4,977,856 4,985,826 Long-term assets Restricted cash 1,477,685 1,431,710 Property, plant and equipment, net 3,413,840 3,297,769 Capitalized lease disposal costs, net 602,404 639,286 Financing lease right-of-use asset — 826 Operating lease right-of-use asset 2,740,704 2,047,733 Goodwill 1,384,255 1,384,255 Patents and other intangibles, net 3,249,893 3,373,563 Total long-term assets 12,868,781 12,175,142 Total assets $ 17,846,637 $ 17,160,968 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 1,219,290 $ 861,883 Accrued liabilities 1,629,960 1,494,665 Unearned revenue 484,568 513,317 Current portion of operating lease right-of-use liability 193,001 150,532 Current installments of notes payable 162,608 308,399 Total current liabilities 3,689,427 3,328,796 Long-term liabilities Accrued long-term liabilities 9,375 37,500 Related party notes payable, net of current portion 1,620,000 1,620,000 Notes payable, net of current portion 181,153 278,897 Asset retirement obligation 1,599,724 1,544,788 Operating lease right-of-use liability, net of current portion 2,588,123 1,940,979 Mandatorily redeemable convertible preferred stock 4,063,000 4,063,000 Total long-term liabilities 10,061,375 9,485,164 Total liabilities 13,750,802 12,813,960 Stockholders' equity Common stock, $ 0.01 par value; 750,000,000 shares authorized; 528,104,105 and 523,553,435 shares issued and outstanding, respectively 5,281,041 5,235,534 Additional paid in capital 126,613,159 126,432,759 Accumulated def

View Full Filing

View this 10-Q filing on SEC EDGAR